Denosumab-related osteonecrosis of the jaw: a case report and management based on pharmacokinetics

Tae Min You; Kang Hee Lee; Soo Hyeon Lee; Wonse Park

doi:10.1016/j.oooo.2015.07.017

Denosumab-related osteonecrosis of the jaw: a case report and management based on pharmacokinetics

Tae Min You, Kang Hee Lee, Soo Hyeon Lee, Wonse Park

Department of Advanced General Dentistry

Research output: Contribution to journal › Article › peer-review

25 Citations (Scopus)

Abstract

Denosumab, a monoclonal antibody against the receptor activator for nuclear factor-kappa B ligand (RANKL), is a recently approved antiresorptive drug that suppresses osteoclast formation by targeting preosteclasts, in contrast to the traditional antiresorptive bisphosphonates that target mature osteoclasts. Osteonecrosis of the jaw (ONJ) is a well-known, if rare, side effect of bisphosphonate therapy; however, cases of ONJ have also been reported since 2010 in patients taking denosumab. We describe here a patient who developed ONJ while receiving denosumab; the pharmacokinetics of denosumab and bisphosphonates are discussed in the context of ONJ management.

Original language	English
Article number	1260
Pages (from-to)	548-553
Number of pages	6
Journal	Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology
Volume	120
Issue number	5
DOIs	https://doi.org/10.1016/j.oooo.2015.07.017
Publication status	Published - 2015 Nov

Bibliographical note

Funding Information:
This research was supported by a Basic Science Research Program through the National Research Foundation of Korea, funded by the Ministry of Science, ICT, and Future Planning (NRF-2013 R1 A1 A 1009513).

Publisher Copyright:
© 2015 Elsevier Inc.

All Science Journal Classification (ASJC) codes

Surgery
Oral Surgery
Pathology and Forensic Medicine
Dentistry (miscellaneous)
Radiology Nuclear Medicine and imaging

Access to Document

10.1016/j.oooo.2015.07.017

Cite this

@article{b27960ab8cd34e2eac5e9b74e0226e07,

title = "Denosumab-related osteonecrosis of the jaw: a case report and management based on pharmacokinetics",

abstract = "Denosumab, a monoclonal antibody against the receptor activator for nuclear factor-kappa B ligand (RANKL), is a recently approved antiresorptive drug that suppresses osteoclast formation by targeting preosteclasts, in contrast to the traditional antiresorptive bisphosphonates that target mature osteoclasts. Osteonecrosis of the jaw (ONJ) is a well-known, if rare, side effect of bisphosphonate therapy; however, cases of ONJ have also been reported since 2010 in patients taking denosumab. We describe here a patient who developed ONJ while receiving denosumab; the pharmacokinetics of denosumab and bisphosphonates are discussed in the context of ONJ management.",

author = "You, {Tae Min} and Lee, {Kang Hee} and Lee, {Soo Hyeon} and Wonse Park",

note = "Funding Information: This research was supported by a Basic Science Research Program through the National Research Foundation of Korea, funded by the Ministry of Science, ICT, and Future Planning (NRF-2013 R1 A1 A 1009513). Publisher Copyright: {\textcopyright} 2015 Elsevier Inc.",

year = "2015",

month = nov,

doi = "10.1016/j.oooo.2015.07.017",

language = "English",

volume = "120",

pages = "548--553",

journal = "Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology",

issn = "2212-4403",

publisher = "Elsevier USA",

number = "5",

}

TY - JOUR

T1 - Denosumab-related osteonecrosis of the jaw

T2 - a case report and management based on pharmacokinetics

AU - You, Tae Min

AU - Lee, Kang Hee

AU - Lee, Soo Hyeon

AU - Park, Wonse

N1 - Funding Information: This research was supported by a Basic Science Research Program through the National Research Foundation of Korea, funded by the Ministry of Science, ICT, and Future Planning (NRF-2013 R1 A1 A 1009513). Publisher Copyright: © 2015 Elsevier Inc.

PY - 2015/11

Y1 - 2015/11

N2 - Denosumab, a monoclonal antibody against the receptor activator for nuclear factor-kappa B ligand (RANKL), is a recently approved antiresorptive drug that suppresses osteoclast formation by targeting preosteclasts, in contrast to the traditional antiresorptive bisphosphonates that target mature osteoclasts. Osteonecrosis of the jaw (ONJ) is a well-known, if rare, side effect of bisphosphonate therapy; however, cases of ONJ have also been reported since 2010 in patients taking denosumab. We describe here a patient who developed ONJ while receiving denosumab; the pharmacokinetics of denosumab and bisphosphonates are discussed in the context of ONJ management.

AB - Denosumab, a monoclonal antibody against the receptor activator for nuclear factor-kappa B ligand (RANKL), is a recently approved antiresorptive drug that suppresses osteoclast formation by targeting preosteclasts, in contrast to the traditional antiresorptive bisphosphonates that target mature osteoclasts. Osteonecrosis of the jaw (ONJ) is a well-known, if rare, side effect of bisphosphonate therapy; however, cases of ONJ have also been reported since 2010 in patients taking denosumab. We describe here a patient who developed ONJ while receiving denosumab; the pharmacokinetics of denosumab and bisphosphonates are discussed in the context of ONJ management.

UR - http://www.scopus.com/inward/record.url?scp=84944176956&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84944176956&partnerID=8YFLogxK

U2 - 10.1016/j.oooo.2015.07.017

DO - 10.1016/j.oooo.2015.07.017

M3 - Article

C2 - 26337218

AN - SCOPUS:84944176956

SN - 2212-4403

VL - 120

SP - 548

EP - 553

JO - Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology

JF - Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology

IS - 5

M1 - 1260

ER -

Denosumab-related osteonecrosis of the jaw: a case report and management based on pharmacokinetics

Abstract

Bibliographical note

All Science Journal Classification (ASJC) codes

Access to Document

Other files and links

Fingerprint

Cite this